Trials / Conditions / Cardiac Surgery Requiring Cardiopulmonary Bypass

Cardiac Surgery Requiring Cardiopulmonary Bypass

16 registered clinical trials studyying Cardiac Surgery Requiring Cardiopulmonary Bypass — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	The Association Between Tau & GFAP and Postoperative Neurological Impairment in Patients Undergoing Cardiac Su NCT06899971	Boston Children's Hospital	—
Recruiting	A Comparison of Renal vs Limb NIRS for Predicting Cardiac Surgery Associated Acute Kidney Injury NCT06705855	University of Utah	—
Recruiting	Oxygen Consumption, Hypoperfusion and Organ Injury After Cardio-pulmonary Bypass NCT06930443	Uppsala University Hospital	—
Not Yet Recruiting	Relationship of Point-of-care Coagulation Assays with Clinical Outcomes in Cardiac Surgery: a Retrospective Co NCT06882759	University Health Network, Toronto	—
Completed	Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery NCT06660823	Ain Shams University	Phase 3
Active Not Recruiting	SIRAKI 02 Posthoc Analysis. NCT06781294	Hospital Universitari de Bellvitge	N/A
Completed	Relation Between Insulinoresistance and Neutrophile to Lymphocyte Ratio in Cardiac Surgery. NCT06945536	Centre Hospitalier Universitaire de Besancon	—
Completed	Biocompatible Versus Non-coated Extracorporeal Circuits in Cardiac Surgery NCT06612060	Polychronis Antonitsis	N/A
Completed	Vancomycin Concentration Analysis in Post-Cardiac Surgery Patients NCT07087301	Pengqiang Du	—
Completed	Comparison of the Performance and Effectiveness of Two Transfusion-Saving Devices: Cell-Saver and SAME NCT06766032	Nantes University Hospital	—
Completed	Clinical Outcomes Between Pulsatile and Non-Pulsatile Flow During Cardiopulmonary Bypass NCT07009730	Tribhuvan University Teaching Hospital, Institute Of Medicine.	—
Completed	Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers NCT01153997	Novo Nordisk A/S	Phase 1
Completed	Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing NCT00914589	Novo Nordisk A/S	Phase 2
Completed	Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypas NCT02239146	Novo Nordisk A/S	Phase 1
Terminated	Use of Activated Recombinant Human Factor VII in Cardiac Surgery NCT00154427	Novo Nordisk A/S	Phase 2
Completed	Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Diseas NCT01562574	Novo Nordisk A/S	Phase 3